MARK LAURENCE BOYS
Pilots in Lyons, CO

License number
Colorado A3814689
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
PO Box 2508, Lyons, CO 80540

Professional information

Mark Boys Photo 1

Therapeutic Pyrazolyl Thienopyridines

US Patent:
2014003, Jan 30, 2014
Filed:
Apr 17, 2013
Appl. No.:
13/864457
Inventors:
Stephen D. Barrett - Hartland MI, US
James B. Kramer - Sylvania OH, US
Mark L. Boys - Lyons CO, US
Huifen Chen - Burlingame CA, US
Assignee:
Medicis Phamaceutical Corporation - Scottsdale AZ
International Classification:
C07D 495/04
US Classification:
514301, 546114
Abstract:
The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof,wherein R, R, R, R, R, R, and Rhave any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.


Mark Boys Photo 2

Therapeutic Pyrazolyl Thienopyridines

US Patent:
7964612, Jun 21, 2011
Filed:
Oct 12, 2007
Appl. No.:
11/871311
Inventors:
Stephen D. Barrett - Hartland MI, US
James B. Kramer - Sylvania OH, US
Mark L Boys - Lyons CO, US
Huifen Chen - Burlingame CA, US
Assignee:
Graceway Pharmaceuticals, LLC - Bristol TN
International Classification:
A61K 31/4365, C07D 495/04
US Classification:
514301, 546114
Abstract:
The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof,.


Mark Boys Photo 3

Therapeutic Pyrazolyl Thienopyridines

US Patent:
8455512, Jun 4, 2013
Filed:
May 20, 2011
Appl. No.:
13/112520
Inventors:
Stephen D. Barrett - Hartland MI, US
James B. Kramer - Sylvania OH, US
Mark L. Boys - Lyons CO, US
Huifen Chen - Burlingame, CN
Assignee:
Medicis Pharmaceutical Corporation - Scottsdale AZ
International Classification:
A61K 31/4365, C07D 495/04
US Classification:
514301, 546114
Abstract:
The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof,.